<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32045742</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-7064</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>166</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuropharmacology</Title>
          <ISOAbbreviation>Neuropharmacology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Astrocyte control of glutamatergic activity: Downstream effects on serotonergic function and emotional behavior.</ArticleTitle>
        <Pagination>
          <StartPage>107914</StartPage>
          <MedlinePgn>107914</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropharm.2019.107914</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0028-3908(19)30485-X</ELocationID>
        <Abstract>
          <AbstractText>Major depressive disorder (MDD) is a leading cause of disability worldwide, with a poorly known pathophysiology and sub-optimal treatment, based on serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors. We review existing theories on MDD, paying special attention to the role played by the ventral anterior cingulate cortex (vACC) or its rodent equivalent, infralimbic cortex (IL), which tightly control the activity of brainstem monoamine neurons (including raphe 5-HT neurons) via descending afferents. Further, astrocytes regulate excitatory synapse activity via glutamate reuptake through astrocytic transporters EAAT1 and EAAT2 (GLAST and GLT-1 in rodents), and alterations of astrocyte number/function have been reported in MDD patients and suicide victims. We recently assessed the impact of reducing GLAST/GLT-1 function in IL on emotional behavior and serotonergic function in rodents. The acute pharmacological blockade of GLT-1 with dihydrokainate (DHK) in rat IL evoked an antidepressant-like effect mediated by local AMPA-R activation and a subsequent enhancement of serotonergic function. No effects were produced by DHK microinfusion in prelimbic cortex (PrL). In the second model, a moderate small interfering RNAs (siRNA)-induced reduction of GLAST and GLT-1 expression in mouse IL markedly increased local glutamatergic neurotransmission and evoked a depressive-like phenotype (reversed by citalopram and ketamine), and reduced serotonergic function and BDNF expression in cortical/hippocampal areas. As for DHK, siRNA microinfusion in PrL did not evoke behavioral/neurochemical effects. Overall, both studies support a critical role of the astrocyte-neuron communication in the control of excitatory neurotransmission in IL, and subsequently, on emotional behavior, via the downstream associated changes on serotonergic function.</AbstractText>
          <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fullana</LastName>
            <ForeName>Neus</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gasull-Camós</LastName>
            <ForeName>Júlia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tarrés-Gatius</LastName>
            <ForeName>Mireia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castañé</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Facultat de Medicina. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Vic, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bortolozzi</LastName>
            <ForeName>Analía</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Artigas</LastName>
            <ForeName>Francesc</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institut d' Investigacions Biomèdiques de Barcelona (IIBB - CSIC), Spain; Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain. Electronic address: francesc.artigas@iibb.csic.es.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Neuropharmacology</MedlineTA>
        <NlmUniqueID>0236217</NlmUniqueID>
        <ISSNLinking>0028-3908</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027341">Excitatory Amino Acid Transporter 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027342">Excitatory Amino Acid Transporter 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493397">SLC1A2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C493394">SLC1A3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3KX376GY7L</RegistryNumber>
          <NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027341" MajorTopicYN="N">Excitatory Amino Acid Transporter 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027342" MajorTopicYN="N">Excitatory Amino Acid Transporter 2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059326" MajorTopicYN="N">Serotonergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antidepressant effects</Keyword>
        <Keyword MajorTopicYN="Y">Astrocytes</Keyword>
        <Keyword MajorTopicYN="Y">Emotional behavior</Keyword>
        <Keyword MajorTopicYN="Y">GLAST</Keyword>
        <Keyword MajorTopicYN="Y">GLT-1</Keyword>
        <Keyword MajorTopicYN="Y">Infralimbic cortex</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32045742</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neuropharm.2019.107914</ArticleId>
        <ArticleId IdType="pii">S0028-3908(19)30485-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
